MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Psychedelic Therapy and Dissociative Drugs
Children
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars) _ Parkinson's Disease
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies_Pain
*Architects: Substance Abuse, Substance Use Disorder (SUD)_Opioid, Alcohol, Tobacco, Etc.
*Augmenting behavioral health research in neuromodulation and psychedelic therapies with a platform for real-time, objective biomarkers as new endpoints to rapidly determine treatment efficacy.
*Biotechnology company pioneering mental health innovation by developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
*Funding: DOD_DHA,USAMRDC_CDMRP (Congressionally Directed Medical Research Program)
*Funding: Pain Management & Control
*Funding: Psychology, Psychiatry, Behavioral & Mental Health, Suicide
*Funding: Substance Use Disorder (SUD)_Drug, Opioid, Alcohol, Tobacco and Addiction
2021: Peter Thiel-backed psychedelics start-up plans to raise $100 million in IPO_ www.cnbc.com
2022: Compass Pathways: De-Risked (But Still Risky) Psychedelics Play Enters Phase 3_ seekingalpha.com
2023: Otsuka adopts new Mindset, dropping $59M to buy Canadian psychedelic biotech
2024: CDMRP_FY24 DMRDP Psychedelic Treatment Research Clinical Trial Award Program Announcement
2024: CDMRP, DMRDP (Defense Medical Research and Development Research Program), Psychedelic Treatment Research Clinical Trial Award
2024: Compass Pathways: No Near-Term Fix For Struggling Psychedelic Therapy Pioneer
2024: NIA_Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required)
2024: NIDA_Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
2025: Brain & Behavior Research Foundation (BBRF) announces recipients of 2025 Distinguished Investigator grants
2025: 10 clinical trials to watch in the first half of 2025
2025: AbbVie Embraces Psychedelic Drug with Up-to-$1.2B Deal for Gilgamesh’s MDD Candidate
2026: NIDA_NOSI: Impacts of Psychedelic and Dissociative Drug Policy Changes on Public Health Outcomes
Biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM"
Brainsway Ltd (NASDAQ:BWAY)
Christian Angermayer, founder and chair of psychedelics company AtaiBeckley.
Clearmind Medicine Inc. NASDAQ CMND is a pre-clinical pharmaceutical company approaching phase 1 clinical trials, that develops novel psychedelic medicines to solve widespread, yet under-served, health problems.
Compass Pathways plc (NASDAQ: CMPS)*
Cybin Inc. (NYSE: CYBN)*
Incannex Healthcare Limited (NASDAQ: IXHL)*
Lykos Therapeutics is a public benefit corporation (PBC) founded to transform mental healthcare by developing investigational psychedelics with an an initial focus on PTSD.
The company is taking the "hub and spoke" approach to biotech building that Roivant has done by setting up, building and selling off its multiple Vants and like Atai Life Sciences has born out through its development of psychedelics-focused startups.
The purpose of this notice of special interest (NOSI) is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of special interest in grant applications that examine the impact of changing state and local psychedelic and dissociative drug policies.
This NOFO invites applications to support a clinical trials network involving multiple institutions to collect safety and early efficacy data of psychedelic-assisted therapy (PAT) in defined groups of older adults living with specific chronic pain conditions.